XERAVA Drug Patent Profile
✉ Email this page to a colleague
When do Xerava patents expire, and what generic alternatives are available?
Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are three patents protecting this drug.
This drug has seventy-eight patent family members in thirty-two countries.
The generic ingredient in XERAVA is eravacycline dihydrochloride. Additional details are available on the eravacycline dihydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Xerava
Xerava will be eligible for patent challenges on August 27, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 19, 2037. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for XERAVA
International Patents: | 78 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 23 |
Patent Applications: | 125 |
Drug Prices: | Drug price information for XERAVA |
What excipients (inactive ingredients) are in XERAVA? | XERAVA excipients list |
DailyMed Link: | XERAVA at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for XERAVA
Generic Entry Date for XERAVA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for XERAVA
US Patents and Regulatory Information for XERAVA
XERAVA is protected by three US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of XERAVA is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting XERAVA
Crystalline forms of eravacycline
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
C7-fluoro substituted tetracycline compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
C7-fluoro substituted tetracycline compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting XERAVA
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-002 | Jun 3, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-001 | Aug 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Tetraphase Pharms | XERAVA | eravacycline dihydrochloride | POWDER;INTRAVENOUS | 211109-002 | Jun 3, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XERAVA
When does loss-of-exclusivity occur for XERAVA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
China
Patent: 0582486
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 29236
Estimated Expiration: See Plans and Pricing
Japan
Patent: 19531321
Estimated Expiration: See Plans and Pricing
Morocco
Patent: 567
Estimated Expiration: See Plans and Pricing
Philippines
Patent: 019500822
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 201903327P
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 190065414
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering XERAVA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2014148509 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | See Plans and Pricing |
Singapore | 10201806714P | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | See Plans and Pricing |
South Korea | 20110058800 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | See Plans and Pricing |
Brazil | PI0916985 | composto de tetraciclina c7-fluoro substituído, composição farmacêutica que o compreende e método para o tratamento ou prevenção de uma infecção ou colonização em um paciente | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XERAVA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2323972 | 2019/013 | Ireland | See Plans and Pricing | PRODUCT NAME: ERAVACYCLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/18/1312 20180920 |
2323972 | PA2019009 | Lithuania | See Plans and Pricing | PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920 |
2323972 | 2019C/511 | Belgium | See Plans and Pricing | PRODUCT NAME: ERAVACYCLINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924 |
2323972 | 122019000024 | Germany | See Plans and Pricing | PRODUCT NAME: ERAVACYCLINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 20180920 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |